Innovita Biological Technology (SH:688253) Xin Lang Zheng Quan·2025-11-07 02:14Core Viewpoint - Innotech's stock price has shown fluctuations, with a year-to-date decline of 8.23% but a recent recovery in the last five trading days, indicating potential market interest and volatility [2]. Company Overview - Innotech Biotechnology Co., Ltd. is located in Fengtai District, Beijing, and was established on February 6, 2006. The company went public on July 28, 2022, and specializes in the research, production, and sales of POCT rapid diagnostic products [2]. - The main revenue composition includes respiratory series (96.49%), other reagent series (2.99%), and preconception series (0.51%) [2]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [2]. Financial Performance - For the period from January to September 2025, Innotech reported a revenue of 330 million yuan, representing a year-on-year decrease of 36.56%. The net profit attributable to the parent company was 131 million yuan, down 46.37% year-on-year [2]. - As of September 30, 2025, the total number of shareholders was 8,037, an increase of 10.57% from the previous period, while the average circulating shares per person decreased by 8.86% to 8,627 shares [2]. Stock Performance and Trading Activity - On November 7, Innotech's stock price increased by 2.15%, reaching 32.77 yuan per share, with a trading volume of 22.37 million yuan and a turnover rate of 1.00%. The total market capitalization stood at 4.489 billion yuan [1]. - The net inflow of main funds was 467,300 yuan, with significant selling activity amounting to 1.666 million yuan, indicating mixed investor sentiment [1]. Dividend Information - Since its A-share listing, Innotech has distributed a total of 152 million yuan in dividends [3]. Institutional Holdings - As of September 30, 2025, the medical device ETF (159883) was the ninth largest circulating shareholder, holding 498,000 shares as a new shareholder [3].